Effect of Levodopa on Speech Dysfluency in Parkinson's Disease.

Objective: To examine the effect of levodopa medication on speech dysfluency in Parkinson's disease. Methods: Fifty-one individuals with Parkinson's disease (IWPD) read aloud during off- and on- medication states. Total speech dysfluencies were calculated from transcriptions of recorded speech samples. Results: Severity of speech dysfluency was not significantly related to the severity of motor symptoms, duration of disease, levodopa equivalent dosage, or age. When the IWPD were divided into two groups based on dysfluency severity, there was a significant group-by-medication state interaction. There was a significant correlation between the medication-related change in speech dysfluency and the off-medication severity of speech dysfluency measure (r = -0.46). Conclusions: The results of this study indicate that levodopa medication can have a significant effect on speech dysfluency. The beneficial levodopa effect appears to be related to the severity of the off-medication speech dysfluency. Results did not provide strong support for the excess dopamine theory of stuttering in IWPD. A dualistic model of the effects of dopamine on speech fluency in PD is proposed.

Effects of Deep Brain Stimulation of the Subthalamic Nucleus Settings on Voice Quality, Intensity, and Prosody in Parkinson's Disease: Preliminary Evidence for Speech Optimization.

OBJECTIVE: To systematically evaluate how different deep brain stimulation of the subthalamic nucleus (STN-DBS) amplitude, frequency, and pulse-width electrical parameter settings impact speech intensity, voice quality, and prosody of speech in Parkinson's disease (PD). METHODS: Ten individuals with PD receiving bilateral STN-DBS treatments were seen for three baseline and five treatment visits. The five treatment visits involved an examination of the standard clinical settings as well as manipulation of different combinations of frequency (low, mid, and high), pulse width (low, mid, and high), and voltage (low, mid, and high) of stimulation. Measures of speech intensity, jitter, shimmer, harmonics-noise ratio, semitone standard deviation, and listener ratings of voice quality and prosody were obtained for each STN-DBS manipulation. RESULTS: The combinations of lower frequency, lower pulse width, and higher voltage settings were associated with improved speech outcomes compared to the current standard clinical settings. In addition, decreased total electrical energy delivered to the STN appears to be associated with speech improvements. CONCLUSIONS: This study provides preliminary evidence that STN-DBS may be optimized for Parkinson-related problems with voice quality, speech intensity, and prosody of speech.

Voice quality severity and responsiveness to levodopa in Parkinson's disease.

The effect of levodopa on perceptual and acoustic measures of voice quality was examined in fifty-one individuals with Parkinson's disease (IWPD). IWPDs produced prolonged vowels while on and off levodopa. Acoustic measures included jitter, shimmer, harmonic-to-noise ratio, cepstral peak prominence and the Acoustic Voice Quality Index. A perceptual measure of overall voice quality was obtained from 3 listeners. When the IWPDs were examined as a group, no significant difference was found between on and off levodopa conditions. In contrast, when IWPDs were split into two groups based on voice quality severity, a significant group-by-medication state interaction emerged. In addition, there was a significant correlation (r = .55) between the magnitude of levodopa-related improvement in perceived voice quality and voice quality severity. In contrast, levodopa-related improvement in voice quality was not correlated with duration of disease or levodopa use. Results do not support the hypothesis of reduced levodopa-responsiveness to voice symptoms as disease duration increases. Instead, the results suggest that the magnitude of the levodopa response may increase with increasing severity of the voice quality symptoms. These results suggest that the severity of speech and voice symptoms needs to be given greater consideration in future studies of levodopa effectiveness in IWPDs.

Deep Brain Stimulation of the Subthalamic Nucleus Parameter Optimization for Vowel Acoustics and Speech Intelligibility in Parkinson's Disease.

Purpose: The settings of 3 electrical stimulation parameters were adjusted in 12 speakers with Parkinson's disease (PD) with deep brain stimulation of the subthalamic nucleus (STN-DBS) to examine their effects on vowel acoustics and speech intelligibility. Method: Participants were tested under permutations of low, mid, and high STN-DBS frequency, voltage, and pulse width settings. At each session, participants recited a sentence. Acoustic characteristics of vowel production were extracted, and naive listeners provided estimates of speech intelligibility. Results: Overall, lower-frequency STN-DBS stimulation (60 Hz) was found to lead to improvements in intelligibility and acoustic vowel expansion. An interaction between speaker sex and STN-DBS stimulation was found for vowel measures. The combination of low frequency, mid to high voltage, and low to mid pulse width led to optimal speech outcomes; however, these settings did not demonstrate significant speech outcome differences compared with the standard clinical STN-DBS settings, likely due to substantial individual variability. Conclusions: Although lower-frequency STN-DBS stimulation was found to yield consistent improvements in speech outcomes, it was not found to necessarily lead to the best speech outcomes for all participants. Nevertheless, frequency may serve as a starting point to explore settings that will optimize an individual's speech outcomes following STN-DBS surgery. Supplemental Material: https://doi.org/10.23641/asha.5899228.